A detailed history of Bank Of America Corp transactions in Ovid Therapeutics Inc. stock. As of the latest transaction made, Bank Of America Corp holds 37,892 shares of OVID stock, worth $39,786. This represents 0.0% of its overall portfolio holdings.

Number of Shares
37,892
Previous 29,534 28.3%
Holding current value
$39,786
Previous $22,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.75 - $1.3 $6,268 - $10,865
8,358 Added 28.3%
37,892 $44,000
Q2 2024

Aug 14, 2024

BUY
$0.7 - $3.34 $7,662 - $36,559
10,946 Added 58.89%
29,534 $22,000
Q1 2024

May 15, 2024

SELL
$2.72 - $4.04 $97,158 - $144,308
-35,720 Reduced 65.77%
18,588 $56,000
Q4 2023

Feb 14, 2024

BUY
$2.98 - $3.78 $5,653 - $7,170
1,897 Added 3.62%
54,308 $174,000
Q2 2023

Aug 14, 2023

BUY
$2.53 - $3.89 $99,426 - $152,873
39,299 Added 299.72%
52,411 $171,000
Q1 2023

May 12, 2023

BUY
$1.88 - $2.85 $18,189 - $27,573
9,675 Added 281.5%
13,112 $33,000
Q4 2022

Feb 10, 2023

SELL
$1.43 - $1.89 $11,889 - $15,713
-8,314 Reduced 70.75%
3,437 $6,000
Q3 2022

Nov 14, 2022

SELL
$1.84 - $2.26 $8,383 - $10,296
-4,556 Reduced 27.94%
11,751 $22,000
Q2 2022

Aug 12, 2022

SELL
$1.69 - $3.31 $42,741 - $83,713
-25,291 Reduced 60.8%
16,307 $35,000
Q1 2022

May 16, 2022

BUY
$2.65 - $3.49 $105,668 - $139,163
39,875 Added 2314.28%
41,598 $131,000
Q4 2021

Feb 08, 2022

SELL
$3.13 - $3.73 $100,000 - $119,169
-31,949 Reduced 94.88%
1,723 $6,000
Q3 2021

Nov 15, 2021

SELL
$3.31 - $4.04 $117,273 - $143,137
-35,430 Reduced 51.27%
33,672 $114,000
Q2 2021

Sep 13, 2021

BUY
$3.3 - $4.49 $228,036 - $310,267
69,102 New
69,102 $270,000

Others Institutions Holding OVID

About Ovid Therapeutics Inc.


  • Ticker OVID
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,419,400
  • Market Cap $73.9M
  • Description
  • Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment o...
More about OVID
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.